These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 28314296)

  • 21. Pancreatic endocrine tumors: tumor blood flow assessed with perfusion CT reflects angiogenesis and correlates with prognostic factors.
    d'Assignies G; Couvelard A; Bahrami S; Vullierme MP; Hammel P; Hentic O; Sauvanet A; Bedossa P; Ruszniewski P; Vilgrain V
    Radiology; 2009 Feb; 250(2):407-16. PubMed ID: 19095784
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Early treatment response evaluation after yttrium-90 radioembolization of liver malignancy with CT perfusion.
    Reiner CS; Morsbach F; Sah BR; Puippe G; Schaefer N; Pfammatter T; Alkadhi H
    J Vasc Interv Radiol; 2014 May; 25(5):747-59. PubMed ID: 24630751
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect on perfusion values of sampling interval of computed tomographic perfusion acquisitions in neuroendocrine liver metastases and normal liver.
    Ng CS; Hobbs BP; Wei W; Anderson EF; Herron DH; Yao JC; Chandler AG
    J Comput Assist Tomogr; 2015; 39(3):373-82. PubMed ID: 25626401
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Proposal of early CT morphological criteria for response of liver metastases to systemic treatments in gastroenteropancreatic neuroendocrine tumors: Alternatives to RECIST.
    de Mestier L; Resche-Rigon M; Dromain C; Lamarca A; La Salvia A; de Baker L; Fehrenbach U; Pusceddu S; Colao A; Borbath I; de Haas R; Rinzivillo M; Zerbi A; Funicelli L; de Herder WW; Selberherr A; Wagner AD; Manoharan P; De Cima A; Lybaert W; Jann H; Prinzi N; Faggiano A; Annet L; Walenkamp A; Panzuto F; Pedicini V; Pitoni MG; Siebenhuener A; Mayerhoefer ME; Ruszniewski P; Vullierme MP
    J Neuroendocrinol; 2023 Jun; 35(6):e13311. PubMed ID: 37345276
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Successful everolimus treatment in a patient with advanced pancreatic neuroendocrine tumor who developed everolimus-induced interstitial lung disease on two occasions: a case report.
    Nakayama Y; Ikeda M; Kojima M; Goto K; Hara M; Okuyama H; Takahashi H; Ohno I; Shimizu S; Mitsunaga S; Okusaka T
    Chemotherapy; 2013; 59(1):74-8. PubMed ID: 23867634
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Can complementary 68Ga-DOTATATE and 18F-FDG PET/CT establish the missing link between histopathology and therapeutic approach in gastroenteropancreatic neuroendocrine tumors?
    Has Simsek D; Kuyumcu S; Turkmen C; Sanlı Y; Aykan F; Unal S; Adalet I
    J Nucl Med; 2014 Nov; 55(11):1811-7. PubMed ID: 25315243
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Whole tumour perfusion of peripheral lung carcinoma: evaluation with first-pass CT perfusion imaging at 64-detector row CT.
    Li Y; Yang ZG; Chen TW; Deng YP; Yu JQ; Li ZL
    Clin Radiol; 2008 Jun; 63(6):629-35. PubMed ID: 18455553
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Contrast-enhancement ratio on multiphase enhanced computed tomography predicts recurrence of pancreatic neuroendocrine tumor after curative resection.
    Arai T; Kobayashi A; Fujinaga Y; Yokoyama T; Shimizu A; Motoyama H; Kitagawa N; Notake T; Shirota T; Fukushima K; Masuo H; Kadoya M; Miyagawa S
    Pancreatology; 2016; 16(3):397-402. PubMed ID: 26850565
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The value of liver magnetic resonance imaging in patients with findings of resectable pancreatic cancer on computed tomography.
    Chew C; O'Dwyer PJ
    Singapore Med J; 2016 Jun; 57(6):334-8. PubMed ID: 27353741
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Quantitative evaluation of CT-perfusion map as indicator of tumor response to transarterial chemoembolization and radiofrequency ablation in HCC patients.
    Ippolito D; Fior D; Bonaffini PA; Capraro C; Leni D; Corso R; Sironi S
    Eur J Radiol; 2014 Sep; 83(9):1665-71. PubMed ID: 24962900
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Computed tomography perfusion analysis of pancreatic carcinoma.
    Klauss M; Stiller W; Fritz F; Kieser M; Werner J; Kauczor HU; Grenacher L
    J Comput Assist Tomogr; 2012; 36(2):237-42. PubMed ID: 22446366
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pancreatic neuroendocrine neoplasms.
    Hörsch D; Bert T; Schrader J; Hommann M; Kaemmerer D; Petrovitch A; Zaknun J; Baum RP
    Minerva Gastroenterol Dietol; 2012 Dec; 58(4):401-26. PubMed ID: 23207615
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Somatostatin receptor scintigraphy in liver metastasis detection from gastroenteropancreatic neuroendocrine tumors.
    Schillaci O; Spanu A; Scopinaro F; Falchi A; Danieli R; Marongiu P; Pisu N; Madeddu G; Delle Fave G; Madeddu G
    J Nucl Med; 2003 Mar; 44(3):359-68. PubMed ID: 12621001
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Monitoring response to antiangiogenic treatment and predicting outcomes in advanced hepatocellular carcinoma using image biomarkers, CT perfusion, tumor density, and tumor size (RECIST).
    Jiang T; Kambadakone A; Kulkarni NM; Zhu AX; Sahani DV
    Invest Radiol; 2012 Jan; 47(1):11-7. PubMed ID: 21512396
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Perfusion CT can predict tumoral grading of pancreatic adenocarcinoma.
    D'Onofrio M; Gallotti A; Mantovani W; Crosara S; Manfrin E; Falconi M; Ventriglia A; Zamboni GA; Manfredi R; Pozzi Mucelli R
    Eur J Radiol; 2013 Feb; 82(2):227-33. PubMed ID: 23127804
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Duodenal neuroendocrine tumors: retrospective evaluation of CT imaging features and pattern of metastatic disease on dual-phase MDCT with pathologic correlation.
    Tsai SD; Kawamoto S; Wolfgang CL; Hruban RH; Fishman EK
    Abdom Imaging; 2015 Jun; 40(5):1121-30. PubMed ID: 25504375
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hepatocellular carcinoma in cirrhotic liver disease: functional computed tomography with perfusion imaging in the assessment of tumor vascularization.
    Ippolito D; Sironi S; Pozzi M; Antolini L; Ratti L; Alberzoni C; Leone EB; Meloni F; Valsecchi MG; Fazio F
    Acad Radiol; 2008 Jul; 15(7):919-27. PubMed ID: 18572129
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prospective Study of 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography for Detecting Gastro-Entero-Pancreatic Neuroendocrine Tumors and Unknown Primary Sites.
    Sadowski SM; Neychev V; Millo C; Shih J; Nilubol N; Herscovitch P; Pacak K; Marx SJ; Kebebew E
    J Clin Oncol; 2016 Feb; 34(6):588-96. PubMed ID: 26712231
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of radiological prognostic factors of hepatic metastases in patients with non-functional pancreatic neuroendocrine tumors.
    Denecke T; Baur AD; Ihm C; Steffen IG; Tischer E; Arsenic R; Pascher A; Wiedenmann B; Pavel M
    Eur J Radiol; 2013 Oct; 82(10):e550-5. PubMed ID: 23891296
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An update on the management of pancreatic neuroendocrine tumors.
    Gao L; Natov NS; Daly KP; Masud F; Chaudhry S; Sterling MJ; Saif MW
    Anticancer Drugs; 2018 Aug; 29(7):597-612. PubMed ID: 29782352
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.